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INTRODUCTION: Sextant prostate biopsy remains the standard technique for the detection of prostate cancer. It is well known 
that after a diagnosis of small acinar proliferation (ASAP) or high grade prostate intraepithelial neoplasia (HGPIN), the possibility 
of finding cancer is approximately 40% and 30%, respectively. 
OBJECTIVE: We aim to analyze follow-up biopsies on patients who initially received a benign diagnosis after exclusion of 
HGPIN and ASAP. 
METHODS: From July 2000 to December 2003, 1177 patients were submitted to sextant extended prostate biopsy in our hospital. 
The mean patient age was 65.5 years old, and the median number of fragments collected at biopsy was 13. HGPIN and ASAP 
were excluded from our study. We only considered patients who had a diagnosis of benign at the first biopsy and were subjected 
to rebiopsies up until May 2005 because of a maintained suspicion of cancer. 
RESULTS: Cancer was initially detected in 524 patients (44.5%), and the diagnosis was benign in 415 (35.3%). Rebiopsy was 
indicated for 76 of the latter patients (18.3%) because of a persistent suspicion of cancer. Eight cases of adenocarcinoma (10.5%) 
were detected, six (75%) at the first rebiopsy. Six patients were submitted to radical prostatectomy, and all tumors were considered 
clinically significant. 
CONCLUSION: Our data indicate that in extended prostate biopsy, the first biopsy detects more cancer, and the first, second, and 
third rebiopsies after an initial benign diagnosis succeed in finding cancer in 7.9% (6/55), 5.9% (1/15) and 20% (1/4) of patients, 
respectively. 
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INTRODUCTION
The systematic sextant prostate biopsy detects cancer 
in only 25-38% of patients1,2, and false-negative results 
have been reported to have an occurrence as high as 23%.3 
Clinicians often face the dilemma of patients who present 
persistently abnormal levels of prostate-specific antigen (PSA) 
or an abnormal digital rectal examination, yet whose biopsies 
are persistently negative. When those patients are submitted to 
rebiopsy, cancer can be detected in 7-22% of cases at the first 
rebiopsy and 2-10% at the second rebiopsy.4-6 
Two histological findings are predictive of prostatic 
adenocarcinoma: ASAP and HGPIN. ASAP is found in 5.5% 
of prostate cancer cases, and can provide false positives due 
to marginal sampling or benign cell growth similar to an 
adenocarcinoma. A second biopsy detects cancer in up to 
60% of patients. 7,8 HGPIN is the only pre-malignant lesion 
reported in 7% of needle biopsies, and rebiopsies detect 
cancer in 25-79% of cases after a diagnosis of HGPIN.
With the introduction of the extended biopsy, new rates 
of HGPIN, ASAP and cancer detection have been described. 340
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After a diagnosis of HGPIN, the possibility of diagnosing 
cancer in a rebiopsy dropped to an average of 21%, while 
ASAP remains a strong predictor of cancer.9
Only one published study has analyzed detection rates for 
extended multi-site prostate biopsy. That study reported that 
rebiopsy, after an initial benign diagnosis, detected cancer in 
13% of cases.5 Here we report cancer detection in rebiopsies 
after a first extended biopsy resulted in a benign diagnosis.
MATERIALS AND METHODS
From July 2000 to December 2003, 1682 biopsies were 
examined in our laboratory. Of these, 505 cases were sent 
for a second opinion and ultimately excluded from the study 
because of the relative prevalence of adenocarcinoma. The 
remaining 1177 biopsies were taken from men with PSA 
levels higher than 4 ng/ml or abnormal results from a digital 
rectal examination. Patients were 32-94 years old (mean, 65.5; 
median, 66). The number of biopsy cores ranged from nine to 
32 (mean, 14; median, 13), and cores were taken bilaterally 
from the medial and lateral zones at the base, mid-gland, and 
apex of the prostate, as described by Presti et al.10
A benign diagnosis was given to 415 patients, and 
rebiopsies were performed on 76 of these patients because 
of persistent suspicion of cancer, increasing PSA levels, or 
abnormal digital rectal examinations. Rebiopsies were taken 
until May 2005. HGPIN- and ASAP-positive cases were 
excluded from the study, because our aim was to analyze 
the results of rebiopsy only in cases initially given a benign 
diagnosis.
The Mann-Whitney test was used to compare the PSA 
levels of patients whose rebiopsies revealed cancer with the 
levels of those with benign rebiopsies.
RESULTS
The results of the 1177 biopsies are shown in Table 1. Of 
all 1177 patients, 415 (35.3%) received a benign diagnosis 
of prostatitis, normal prostatic tissue, atrophy, or glandular 
hyperplasia. 
Among the 415 men receiving the benign diagnosis, 
mean age was 63.7 (median, 63; range, 49-82). The mean 
and median number of biopsy cores was 13 (range, 9 to 
20). 
PSA levels varied from 0.8 to 34 ng/ml (mean, 9.04 ng/
ml; median, 8.00 ng/ml). Of the 415 patients, 76 (18.3%) 
were subjected to rebiopsies because of persistent suspicion 
of cancer. A total of 99 rebiopsies were performed. A single 
rebiopsy was performed in 53 patients (69.7%), two were 
performed in 17 patients (22.4%), three rebiopsies were 
performed in five patients (6.6%), and four were conducted 
on a single patient (1.3%). 
The mean interval between the first and second biopsies 
was 20 months (median, 17; range, 1-49). The mean interval 
between second and third biopsies was 27 months (median, 
23; range, 12-54), and the mean interval for the fourth biopsy 
was 36 months (median, 32; range, 22-57). One patient was 
submitted to a fifth biopsy 43 months after the first one. The 
results of rebiopsies are shown in Table 2. 
Adenocarcinoma was detected in eight patients (10.5%): 
six (6/76) at the first rebiopsy, one (1/17) at the second 
rebiopsy, and one patient who was subjected to two 
rebiopsies and then to a transurethral resection (TUR) that 
led to a diagnosis of adenocarcinoma (1/5). The Gleason 
grade varied from 5 to 8 (mean, 6.75; median, 7). The 
mean percentage of tumor-positive fragments was 10.9% 
(median, 6.3%; range, 5-18.8%). The total percentage of 
tumor-positive fragments ranged from 1.3% to 6% (mean, 
3.22%; median, 3%). The adenocarcinoma diagnosed in 
Table 1 ­ Results of 1177 biopsies examined between July 
2000 and December 2003
Diagnosis N %
Adenocarcinoma 524 44.5
Benign 415 35.3
HGPIN  181 15.4
HGPIN + ASAP 32 2.7
ASAP 25 2.1
Table 2 ­ Rebiopsies after benign diagnosis in 76 patients
Rebiopsy
Diagnosis
Benign Adenocarcinoma PIN ASAP HGPIN+ASAP
1 55 (72.4) 6 (7.9) 11 (14.5) 3 (3.9) 1 (1.3)
2 15 (88.2) 1 (5.9) 1 (5.9) - -
3 4 (80.0) 1 (20.0)* - - -
4 1 (100.0) - - - -
*Adenocarcinoma diagnosed in TUR341
CLINICS 2008;63:339-42 Prostate cancer detection at rebiopsy after an initial benign diagnosis
Leite KRM et al.
TUR had a Gleason score of 7 (3+4) affecting 20% of the 
specimen (pT1b). 
The PSA levels were not significantly different between 
patients who showed benign or malignant rebiopsy results. 
The mean and median PSA for patients with adenocarcinoma 
were, respectively, 11.9 ng/ml and 9 ng/ml (range, 6.15-34 
ng/ml). For patients without carcinoma, the mean PSA was 
8.9 ng/ml (median, 7.9; range, 0.8-24 ng/ml; p (with vs. 
without) =0.452).
Six patients were submitted to radical prostatectomy 
after a diagnosis of adenocarcinoma. All were considered 
clinically  significant  (>0.5  cc,  not  confined,  with 
Gleason patterns of at least 4 or 5). The results of radical 
prostatectomy are given in Table 3. 
DISCUSSION
We have shown that, after extended sextant biopsies, 
10.5% of patients who initially received benign diagnoses 
(but in whom cancer was a persistent suspicion) turned out 
to have detectable adenocarcinoma upon rebiopsy. Only the 
series published by Mian et al. contains data on extended 
biopsies, and they detected cancer in 13% of cases initially 
diagnosed as benign.5 The results published by Singh et 
al.7 were based on 12 core biopsies, and they reported a 
cancer detection rate of 21%. In their study, however, they 
did not restrict their analysis to patients initially diagnosed 
as benign, and they also included HGPIN-positive cases, 
where HGPIN was the higher risk factor to find cancer in 
the rebiopsy. 
The sensitivity and specificity of screening tests for 
prostate cancer cannot be determined with certainty because 
biopsies are not performed on patients with negative 
screening results. Nevertheless, it is known that as many as 
19% of patients with initially negative prostate biopsies are 
found to have cancer upon rebiopsy.
It is interesting to note that, after a first extended biopsy, 
we diagnosed cancer in 44.5% of our patients, which is 
higher than the 25-38% classically reported for the sextant 
strategy.1,2 Studies based on the traditional strategy detect 
cancer in up to 30% of rebiopsies.11 These results show that 
diagnosis comes late for many patients, in addition to the fact 
that correct diagnosis requires repeated, invasive biopsies 
that are not without risk. 
All data available in the literature are based on sextant 
biopsies, and the significance of basing results on 10 or 
more biopsy cores is not yet fully known. As suggested by 
O’Dowd et al., improving the success rate of biopsies may 
require increasing the number of fragments taken at the first 
prostate biopsy.12 Those authors argue that a better strategy 
for detecting cancer at the first biopsy is needed, given 
that they detected adenocarcinoma in almost 20% of their 
patients upon rebiopsy.
The post-sextant era has seen a change in the detection 
rate upon rebiopsy. A recent study by Moore et al.13 showed 
that when 10 or more cores are taken at the first biopsy, 
the possibility of finding cancer drops to 4.5% following 
a diagnosis of HGPIN.10 We published a similar study of 
rebiopsies in 53 patients positive for HGPIN, in which we 
reported cancer detection in 13.2% of the cases.6 
Djavan et al.14 performed biopsies every six or eight 
weeks, and they detected cancer in 22%, 10%, 5% and 4% 
of four successive biopsies, respectively. While our study is 
closer to standard practice for urology outpatient care than 
theirs, their numbers are very similar to ours. The overall 
diagnosis of cancer in repeated biopsies was 7.5% in their 
study, compared to 10.5% in our case, almost all of them 
at the first rebiopsy. However, Djavan et al. suggested that, 
because of the difficulty of detecting extremely small tumors, 
biopsies beyond two were justified only for men at very high 
risk of developing cancer. Our data contradict this idea. All 
cancers we detected were clinically significant, including 
a patient in whom carcinonoma was diagnosed in a TUR 
following three biopsies. In this case the adenocarcinoma 
Table 3 ­ Results of radical prostatectomy of six patients 
Patient PSA 
ng/mL
Weight 
(g)
Gleason 
score
Percentage 
of tumor
Volume 
(cc)
% of Gleason 
pattern 4
Tumor 
location
Stage 
TNM 2002
1 13.4 34.5 8 (4+4) 6 1.6 100  PLBM pT2bN0
2 6.2 43.2 4 (2+2) 2 0.8 0  TLM pT2aN0
3 13.1 98.9 5 (3+2) 1 0.9 0  PLA pT2aN0
4 14.8 89.8 7 (4+3) 6 6.0 60  PLM pT2bN0
5 9.2 102.9 7 (4+3) 4 4.2 64  PRA pT2aN0
6 29.0 44.1 7 (3+4) 12 5.3 48  PRLB pT3aN0
Note: In patients 1–4, adenocarcinoma was diagnosed at the first rebiopsy, in patient 5 at the second rebiopsy, and in patient 6 after TUR. PLBM, periph-
eral left base and medium; TLM, transitional – left medium; PLA, peripheral – left apex; PLM, peripheral – left medium; PRA, peripheral – right apex; 
PRLB, peripheral – right and left base342
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was pT3a, the Gleason score was 7 (3+4), and tumor volume 
was 5.3 cc. Roehl et al. report similar results: by taking up 
to six biopsies, 99% of cancers were detected, and only 
1% were considered clinically insignificant.15 Relative 
PSA levels can be informative in these situations, but the 
absolute levels are unhelpful for diagnosis. We have shown 
no significant difference in PSA between patients who, upon 
rebiopsy, were diagnosed with cancer and those who were 
not diagnosed with cancer. Increased PSA level does not 
always correspond to a diagnosis of cancer at rebiopsy. Mian 
et al.5 showed a positive biopsy rate of only 17% in the group 
that they considered to be at high risk of prostate cancer due 
to abnormal digital rectal examinations or a percentage of 
free PSA of 15% or less, or previous diagnosis of HGPIN or 
ASAP. The free-to-total prostate-specific antigen ratio may 
be diagnostically useful, although, according to Ciatto et 
al.16, this ratio should never be used to exclude rebiopsy in 
patients for whom suspicion of cancer persists. 
The rebiopsies in our investigation were taken at longer 
intervals than in previous studies: the median was 17, 23, 
and 32 months for the first, second, and third rebiopsies, 
respectively. This is closer to the real practice of urologists, 
and it seems to be a reasonable scheme for a cancer-
screening program. Morbidity associated with rebiopsies, 
particularly those conducted at short intervals, has been 
a concern in the past. However, postponing the biopsy 
procedure did not appear to pose a problem for our patients 
with cancer, almost all of whom had confined tumors. 
Roobol et al. came to the same conclusion.17 In a study of 
prostate rebiopsy of patients after an initial negative result, 
they detected cancer in 8% of cases after an interval of four 
years. The tumors in all cancer patients were confined to 
organs and were amenable to curative treatment.
In conclusion, we have shown that the sextant extended 
multisite prostate biopsy detects more cancer than the 
traditional sextant scheme. Of all the patients included in our 
study, 18% were rebiopsied after an initial benign diagnosis 
because of persistent suspicion of cancer, and malignancy 
was detected in 7.9% patients (6/55) at a second biopsy, 5.9% 
(1/15) at a third biopsy, and 20.0% (1/4) at a fourth biopsy. 
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